Cost-effectiveness of empagliflozin for the treatment of heart failure with reduced ejection fraction in China
AimTo determine the pharmacoeconomics of empagliflozin for the treatment of heart failure (HF) with reduced ejection fraction in China and to provide evidence-based reference for clinical rational drug selection and medical decision-making.Research design and methodsWe used the Markov model to evalu...
Zapisane w:
| Główni autorzy: | , , , , |
|---|---|
| Format: | Artigo |
| Język: | Inglês |
| Wydane: |
Frontiers Media S.A.
2022-11-01
|
| Seria: | Frontiers in Cardiovascular Medicine |
| Hasła przedmiotowe: | |
| Dostęp online: | https://www.frontiersin.org/articles/10.3389/fcvm.2022.1022020/full |
| Etykiety: |
Nie ma etykietki, Dołącz pierwszą etykiete!
|